1. Staff ALM (2017) Marijuana Legalization Across the U.S.
2. Terry McElrath YM, et al. (2017) Longitudinal patterns of marijuana use across ages 18-50 in a US national sample: A descriptive examination of predictors
and health correlates of repeated measures latent class membership. Drug Alcohol Depend 171: 70-83.
3. Tai S, Fantegrossi WE (2017) Pharmacological and Toxicological Effects of Synthetic Cannabinoids and Their Metabolites. Curr Top Behav
Neurosci 32: 249-262.
4. U.S Department of Health and Human Services, CDC, NCHS, (2017) Underlying Cause of Death 1999-2013 on CDC WONDER Online Database.
5. Sardarinia, M, et al. (2016) Risk Factors for Incidence of Cardiovascular Diseases and All-Cause Mortality in a Middle Eastern Population over a Decade
Follow-up: Tehran Lipid and Glucose Study. PLoS One11: e0167623.
6. Jayakody AA, et al. (2006) Illicit and traditional drug use among ethnic minority adolescents in East London. Public Health 120: 329-338.
7. Pagotto U, et al. (2006) the emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev 27: 73-100.
8. Liu J, et al. (2012) Hepatic cannabinoid receptor-1 mediates diet-induced insulin resistance via inhibition of insulin signaling and clearance in mice.
Gastroenterology 142: 1218-1228.
9. Racine C, et al. (2015) Metabolic Effects of Marijuana Use among Blacks. J Dis Glob Health 4: 9-16.
10. Muniyappa R, et al. (2013) Metabolic effects of chronic cannabis smoking. Diabetes Care 36: 2415-2422.
11. Foltin RW, Fischman MW, Byrne MF (1988) Effects of smoked marijuana on food intake and body weight of humans living in a residential laboratory.
Appetite 11: 1-14.
12. Hollister LE, Reaven GM (1974) Delta-9-tetrahydrocannabinol and glucose tolerance. Clin Pharmacol Ther 16: 297-302.
13. Rodondi N, et al. (2006) Marijuana use, diet, body mass index, and cardiovascular risk factors (from the CARDIA study). Am J Cardiol 98: 478-484.
14. Vickers SP, Kennett GA (2005) Cannabinoids and the regulation of ingestive behaviour. Curr Drug Targets 6: 215-223.
15. Riggs PK, et al. (2012) A pilot study of the effects of cannabis on appetite hormones in HIV-infected adult men. Brain Res 1431: 46-52.
16. Smit E, Crespo CJ (2001) Dietary intake and nutritional status of US adult marijuana users: results from the Third National Health and Nutrition Examination
Survey. Public Health Nutr 4: 781-786.
17. Mittleman MA, et al. (2001) Triggering myocardial infarction by marijuana. Circulation 103: 2805-2809.
18. Ladeiras LR, et al. (2017) The Ratio Between Visceral and Subcutaneous Abdominal Fat Assessed by Computed Tomography Is an Independent Predictor of
Mortality and Cardiac Events. Rev Esp Cardiol (Engl Ed) 70: 331-337.
19. Schlecht I, et al. (2017) Visceral adipose tissue but not subcutaneous adipose tissue is associated with urine and serum metabolites.
PLoS One 12: e0175133.
20. Gonzalez N, et al. (2017) Regulation of visceral and epicardial adipose tissue for preventing cardiovascular injuries associated to obesity and diabetes.
Cardiovasc Diabetol 16: 44.
21. Dol Gleizes F, et al. (2009) Rimonabant, a selective cannabinoid CB1 receptor antagonist, inhibits atherosclerosis in LDL receptor-deficient mice.
Arterioscler Thromb Vasc Biol 29: 12-8.
22. Klein TW, Cabral GA (2006) Cannabinoid-induced immune suppression and modulation of antigen-presenting cells. J Neuroimmune Pharmacol 1: 50-64.
23. Ribeiro A, et al. (2012) Cannabidiol, a non-psychotropic plant-derived cannabinoid, decreases inflammation in a murine model of acute lung injury: role
for the adenosine A(2A) receptor. Eur J Pharmacol 678: 78-85.
24. Burstein S (2015) Cannabidiol (CBD) and its analogs: a review of their effects on inflammation. Bioorg Med Chem 23: 1377-1385.